Search

Your search keyword '"Pala, Laura"' showing total 450 results
Start Over Author "Pala, Laura"
450 results on '"Pala, Laura"'

1. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

Author

Pala, Laura, Pagan, Eleonora, Sala, Isabella, Oriecuia, Chiara, Oliari, Matteo, De Pas, Tommaso, Specchia, Claudia, Cocorocchio, Emilia, Zattarin, Emma, Rossi, Giovanna, Catania, Chiara, Ceresoli, Giovanni Luca, Laszlo, Daniele, Canzian, Jacopo, Valenzi, Elena, Viale, Giuseppe, Gelber, Richard D., Mantovani, Alberto, Bagnardi, Vincenzo, and Conforti, Fabio

Published
2024
Full Text
View/download PDF

7. A chemical approach to combatting cardiovascular reperfusion injury

Author

Pala, Laura

Subjects
615.1, QD Chemistry
Abstract

The research discussed in this thesis aims at combatting diseases generated by mitochondria dysfunction. Chapter 1 introduces mitochondria structure, roles and functionality, together with various strategies to improve the delivery of drugs to different targets and specifically to mitochondria. The most common strategies to target specifically mitochondria have been described, and in Chapter 2 the investigation of new strategies has been reported. This involves the synthesis of a small library of carboxylic acid and ester derivatives of phosphonium salts, in vitro results on isolated mitochondria and computational calculations. The obtained data all together support a model of uptake proposed in Chapter 2. The research discussed in chapter 3 aims to ameliorate the effects of ischaemia/reperfusion injury, one of the deadliest cardiovascular diseases, for which no effective treatment is present in clinical practice. Previous research elucidated that the disease originates from mitochondria dysfunction and showed cardioprotection in vivo by delivering malonate as dimethyl malonate. Malonate is a known inhibitor of succinate dehydrogenase, an enzyme at the interface of the ETC and TCA cycle. The research described in this chapter presents libraries of compounds designed to improve the delivery of malonate to mitochondria. Synthesis and in vitro and in vivo results are shown, concluding with the identification of a few lead compounds. In Chapter 4 a common feature in pathologies caused by mitochondria dysfunctions was discussed. This is the oxidative damage deriving from the production of ROS. The primary ROS is superoxide and its identification and quantification with reliable methods is crucial for the understanding of diseases. Hydroethidine is one of the best molecular probes used for the selective identification and quantification of superoxide forming a unique fluorescent species. However, hydroethidine presents some disadvantages, namely fluorescence quenching in water, which lowers the limit of detection, and intercalation to DNA, which increases the fluorescent response. The mechanism of fluorescence quenching in water is not fully understood and a few different mechanisms have been proposed in the literature. Several target compounds were designed aiming to block the DNA intercalation and the fluorescent quenching in water, in order to obtain a more suitable molecular probe for the superoxide detection for in vivo applications. The multistep synthesis of the designed targets is described together with the various routes investigated. Preliminary emission results are reported as well.

Published
2019
Full Text
View/download PDF

9. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2022
Full Text
View/download PDF

10. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

Author

Conforti, Fabio, Zucali, Paolo Andrea, Pala, Laura, Catania, Chiara, Bagnardi, Vincenzo, Sala, Isabella, Della Vigna, Paolo, Perrino, Matteo, Zagami, Paola, Corti, Chiara, Stucchi, Sara, Barberis, Massimo, Guerini-Rocco, Elena, Di Venosa, Benedetta, De Vincenzo, Fabio, Cordua, Nadia, Santoro, Armando, Giaccone, Giuseppe, and De Pas, Tommaso Martino

Published
2022
Full Text
View/download PDF

12. Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS)

Author

Dicembrini, Ilaria, Vitale, Valentina, Cosentino, Claudia, Cresci, Barbara, Pala, Laura, Pieri, Maria, Yannas, Dimitri, Vannucci, Matteo, Zago, Elena, Romani, Alessia, Delli Poggi, Chiara, Mariani, Sara Liana, Scoccimarro, Daniele, Cocchetti, Carlotta, Monami, Matteo, and Mannucci, Edoardo

Published
2022
Full Text
View/download PDF

15. 'Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.'

Author

Pala, L, Sala, I, Pagan, E, De Pas, T, Zattarin, E, Catania, C, Cocorocchio, E, Rossi, G, Laszlo, D, Ceresoli, G, Canzian, J, Valenzi, E, Bagnardi, V, Conforti, F, Pala, Laura, Sala, Isabella, Pagan, Eleonora, De Pas, Tommaso, Zattarin, Emma, Catania, Chiara, Cocorocchio, Emilia, Rossi, Giovanna, Laszlo, Daniele, Ceresoli, Giovanni, Canzian, Jacopo, Valenzi, Elena, Bagnardi, Vincenzo, Conforti, Fabio, Pala, L, Sala, I, Pagan, E, De Pas, T, Zattarin, E, Catania, C, Cocorocchio, E, Rossi, G, Laszlo, D, Ceresoli, G, Canzian, J, Valenzi, E, Bagnardi, V, Conforti, F, Pala, Laura, Sala, Isabella, Pagan, Eleonora, De Pas, Tommaso, Zattarin, Emma, Catania, Chiara, Cocorocchio, Emilia, Rossi, Giovanna, Laszlo, Daniele, Ceresoli, Giovanni, Canzian, Jacopo, Valenzi, Elena, Bagnardi, Vincenzo, and Conforti, Fabio

Abstract

Introduction: To provide evidence explaining the poor association between pCR and patients’ long-term outcome at trial-level in neoadjuvant RCTs for breast cancer (BC), we performed a systematic-review and meta-analysis of all RCTs testing neoadjuvant treatments for early-BC and reporting the hazard ratio of DFS (HRDFS) for the intervention versus control arm stratified by pathological response type (i.e., pCR yes versus no). Methods: The objective was to explore differences of treatment effects on DFS across patients with and without pCR. We calculated the pooled HRDFS in the two strata of pathological response (i.e., pCR yes versus no) using a random-effects model, and assessed the difference between these two estimates using an interaction test. Results: Ten RCTs and 8496 patients were included in the analysis. Patients obtaining pCR in the intervention-arm had a higher, although not statistically significant, risk of DFS-event as compared with patients obtaining pCR in the control-arm: the pooled HRDFS for the experimental versus control arm was 1.23 (95%CI, 0.91–1.65). On the opposite, the risk of DFS-event was higher for control as compared with the intervention-arm in the stratum of patients without pCR: the pooled HRDFS was 0.86 (95%CI, 0.78–0.95). Treatment effect on DFS was significantly different according to pathological response type (interaction test p: 0.014). Conclusion: We reported new evidence that contributes to explaining the poor surrogacy value of pCR at trial-level in neoadjuvant RCTs for early-BC.

Published
2024

17. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2023
Full Text
View/download PDF

18. Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study

Author

Lombardi, Carlo Mario, Specchia, Claudia, Conforti, Fabio, Rovere, Maria Teresa La, Carubelli, Valentina, Agostoni, Piergiuseppe, Carugo, Stefano, Danzi, Gian Battista, Guazzi, Marco, Mortara, Andrea, Piepoli, Massimo, Porto, Italo, Sinagra, Gianfranco, Volterrani, Maurizio, Ameri, Pietro, Gnecchi, Massimiliano, Leonardi, Sergio, Merlo, Marco, Iorio, Annamaria, Bellasi, Antonio, Canale, Claudia, Camporotondo, Rita, Catagnano, Francesco, Dalla Vecchia, Laura Adelaide, Di Pasquale, Mattia, Giovinazzo, Stefano, Maccagni, Gloria, Mapelli, Massimo, Margonato, Davide, Monzo, Luca, Nuzzi, Vincenzo, Oriecuia, Chiara, Pala, Laura, Peveri, Giulia, Pozzi, Andrea, Provenzale, Giovanni, Sarullo, Filippo, Adamo, Marianna, Tomasoni, Daniela, Inciardi, Riccardo Maria, Senni, Michele, and Metra, Marco

Published
2022
Full Text
View/download PDF

20. Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study

Author

Ridolfi, Laura, De Rosa, Francesco, Petracci, Elisabetta, Tanda, Enrica Teresa, Marra, Elena, Pigozzo, Jacopo, Marconcini, Riccardo, Guida, Michele, Cappellini, Gian Carlo Antonini, Gallizzi, Giulia, Occelli, Marcella, Pala, Laura, Gambale, Elisabetta, Bersanelli, Melissa, Galdo, Giovanna, Cortellini, Alessio, Morgese, Francesca, Zoratto, Federica, Stucci, Luigia Stefania, Strippoli, Sabino, and Guidoboni, Massimo

Published
2020
Full Text
View/download PDF

23. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

Author

Santini, Daniele, Zeppola, Tea, Russano, Marco, Citarella, Fabrizio, Anesi, Cecilia, Buti, Sebastiano, Tucci, Marco, Russo, Alessandro, Sergi, Maria Chiara, Adamo, Vincenzo, Stucci, Luigia S., Bersanelli, Melissa, Mazzaschi, Giulia, Spagnolo, Francesco, Rastelli, Francesca, Giorgi, Francesca Chiara, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Siringo, Marco, Ferrari, Marco, Marconcini, Riccardo, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Ghidini, Michele, Nigro, Olga, Grossi, Francesco, De Tursi, Michele, Di Marino, Pietro, Pala, Laura, Queirolo, Paola, Bracarda, Sergio, Macrini, Serena, Gori, Stefania, Inno, Alessandro, Zoratto, Federica, Tanda, Enrica T., Mallardo, Domenico, Vitale, Maria Grazia, Talbot, Thomas, Ascierto, Paolo A., Pinato, David J., Ficorella, Corrado, Porzio, Giampiero, and Cortellini, Alessio

Published
2021
Full Text
View/download PDF

24. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.

Author

Sala, Isabella, Pagan, Eleonora, Pala, Laura, Oriecuia, Chiara, Musca, Marco, Specchia, Claudia, De Pas, Tommaso, Cortes, Javier, Giaccone, Giuseppe, Postow, Michael, Gelber, Richard D., Bagnardi, Vincenzo, and Conforti, Fabio

Subjects
IMMUNE checkpoint inhibitors, CLINICAL trials, OVERALL survival, SURVIVAL rate, TREATMENT effectiveness, IPILIMUMAB
Abstract

Introduction: There is debate on which are the best surrogate endpoint and metric to capture treatment effect on overall survival (OS) in RCTs testing immune-checkpoint inhibitors (ICIs). Methods: We systematically searched for RCTs testing ICIs in patients with advanced solid tumors. Inclusion criteria were: RCTs i) assessing PD-(L)1 and CTLA-4 inhibitors either as monotherapy or in combination with another ICI, and/or targeted therapy, and/or chemotherapy, in patients with advanced solid tumors; ii) randomizing at least 100 patients. We performed a meta-analysis of RCTs to compare the surrogacy value of PFS and modified-PFS (mPFS) for OS in RCTs testing ICIs, when the treatment effect is measured by the hazard ratio (HR) for OS, and by the HR and the ratio of restricted mean survival time (rRMST) for PFS and mPFS. Results: 61 RCTs (67 treatment comparisons and 36,034 patients) were included in the analysis. In comparisons testing ICI plus chemotherapy, HRPFS and HRmPFS both had a strong surrogacy value (R2 = 0.74 and R2 = 0.81, respectively). In comparisons testing ICI as monotherapy, HRPFS was the best surrogate, although having a moderate correlation (R2 = 0.58). In comparisons testing ICI plus other treatment(s), the associations were very weak for all the surrogate endpoints and treatment effect measures, with R2 ranging from 0.01 to 0.22. Conclusion: In RCTs testing ICIs, the value of potential surrogates for HROS was strongly affected by the type of treatment(s) tested. The evidence available supports HRPFS as the best surrogate, and disproves the use of alternative endpoints, such as the mPFS, or treatment effect measures, such as the RMST. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

Author

Conforti, Fabio, primary, Pala, Laura, additional, De Pas, Tommaso, additional, Zattarin, Emma, additional, Catania, Chiara, additional, Cocorocchio, Emilia, additional, Rossi, Giovanna, additional, Laszlo, Daniele, additional, Colleoni, Marco, additional, Zambelli, Alberto, additional, Hortobagyi, Gabriel N., additional, Cortes, Javier, additional, Piccart, Martine J., additional, Dowsett, Mitch, additional, Gelber, Richard D., additional, and Viale, Giuseppe, additional

Published
2023
Full Text
View/download PDF

27. Succinate accumulation drives ischaemia-reperfusion injury during organ transplantation

Author

Martin, Jack L., Costa, Ana S. H., Gruszczyk, Anja V., Beach, Timothy E., Allen, Fay M., Prag, Hiran A., Hinchy, Elizabeth C., Mahbubani, Krishnaa, Hamed, Mazin, Tronci, Laura, Nikitopoulou, Efterpi, James, Andrew M., Krieg, Thomas, Robinson, Alan J., Huang, Margaret M., Caldwell, Stuart T., Logan, Angela, Pala, Laura, Hartley, Richard C., Frezza, Christian, Saeb-Parsy, Kourosh, and Murphy, Michael P.

Published
2019
Full Text
View/download PDF

29. Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials

Author

Pala, Laura, primary, De Pas, Tommaso, additional, Pagan, Eleonora, additional, Sala, Isabella, additional, Catania, Chiara, additional, Zattarin, Emma, additional, Arnone, Paolo, additional, Grassi, Massimo M., additional, Colleoni, Marco, additional, Wolff, Antonio C., additional, Cortes, Javier, additional, Piccart, Martine, additional, Gelber, Richard D., additional, Viale, Giuseppe, additional, Bagnardi, Vincenzo, additional, and Conforti, Fabio, additional

Published
2023
Full Text
View/download PDF

30. Corrigendum to ‘Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study’ [Eur J Cancer 171 (2022) 183–192]

Author

Conforti, Fabio, primary, Gronchi, Alessandro, additional, Penel, Nicholas, additional, Jones, Robin L., additional, Broto, Javier M., additional, Sala, Isabella, additional, Bagnardi, Vincenzo, additional, Napolitano, Andrea, additional, Pala, Laura, additional, Pennacchioli, Elisabetta, additional, Catania, Chiara, additional, Queirolo, Paola, additional, Grigani, Giovanni, additional, Merlini, Alessandra, additional, Stacchiotti, Silvia, additional, Comandone, Alessandro, additional, Vincenzi, Bruno, additional, Quagliuolo, Vittorio, additional, Bertuzzi, Alexia, additional, Boglione, Antonella, additional, Palassini, Elena, additional, Baldi, Giacomo G., additional, Blay, Jean-Yves, additional, Ryckewaert, Thomas, additional, Toulmonde, Maud, additional, Italiano, Antoine, additional, Le Cesne, Axel, additional, Ray-Coquard, Isabelle, additional, Cruz, Josefina, additional, Hernández-León, Carmen N., additional, Trufero, Javier M., additional, da Silva Moura, David, additional, Muñiz, Nadia H., additional, and De Pas, Tommaso, additional

Published
2023
Full Text
View/download PDF

31. Therapeutic Education

Author

Rotella, Carlo, Cresci, Barbara, Pala, Laura, Dicembrini, Ilaria, Sbraccia, Paolo, editor, Nisoli, Enzo, editor, and Vettor, Roberto, editor

Published
2016
Full Text
View/download PDF

35. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Conforti, Fabio, primary, Pala, Laura, primary, Pagan, Eleonora, primary, Bagnardi, Vincenzo, primary, De Pas, Tommaso, primary, Queirolo, Paola, primary, Pennacchioli, Elisabetta, primary, Catania, Chiara, primary, Cocorocchio, Emilia, primary, Ferrucci, Pier Francesco, primary, Saponara, Maristella, primary, Orsolini, Gianmarco, primary, Zagami, Paola, primary, Nicoló, Eleonora, primary, De Marinis, Filippo, primary, Tortora, Giampaolo, primary, Bria, Emilio, primary, Minucci, Saverio, primary, Joffe, Hadine, primary, Veronesi, Paolo, primary, Wargo, Jennifer, primary, Rosenthal, Rachel, primary, Swanton, Charles, primary, Mantovani, Alberto, primary, Gelber, Richard D., primary, Viale, Giuseppe, primary, Goldhirsch, Aron, primary, and Giaccone, Giuseppe, primary

Published
2023
Full Text
View/download PDF

36. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Conforti, Fabio, primary, Pala, Laura, primary, Pagan, Eleonora, primary, Bagnardi, Vincenzo, primary, De Pas, Tommaso, primary, Queirolo, Paola, primary, Pennacchioli, Elisabetta, primary, Catania, Chiara, primary, Cocorocchio, Emilia, primary, Ferrucci, Pier Francesco, primary, Saponara, Maristella, primary, Orsolini, Gianmarco, primary, Zagami, Paola, primary, Nicoló, Eleonora, primary, De Marinis, Filippo, primary, Tortora, Giampaolo, primary, Bria, Emilio, primary, Minucci, Saverio, primary, Joffe, Hadine, primary, Veronesi, Paolo, primary, Wargo, Jennifer, primary, Rosenthal, Rachel, primary, Swanton, Charles, primary, Mantovani, Alberto, primary, Gelber, Richard D., primary, Viale, Giuseppe, primary, Goldhirsch, Aron, primary, and Giaccone, Giuseppe, primary

Published
2023
Full Text
View/download PDF

37. Figure S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Conforti, Fabio, primary, Pala, Laura, primary, Pagan, Eleonora, primary, Bagnardi, Vincenzo, primary, De Pas, Tommaso, primary, Queirolo, Paola, primary, Pennacchioli, Elisabetta, primary, Catania, Chiara, primary, Cocorocchio, Emilia, primary, Ferrucci, Pier Francesco, primary, Saponara, Maristella, primary, Orsolini, Gianmarco, primary, Zagami, Paola, primary, Nicoló, Eleonora, primary, De Marinis, Filippo, primary, Tortora, Giampaolo, primary, Bria, Emilio, primary, Minucci, Saverio, primary, Joffe, Hadine, primary, Veronesi, Paolo, primary, Wargo, Jennifer, primary, Rosenthal, Rachel, primary, Swanton, Charles, primary, Mantovani, Alberto, primary, Gelber, Richard D., primary, Viale, Giuseppe, primary, Goldhirsch, Aron, primary, and Giaccone, Giuseppe, primary

Published
2023
Full Text
View/download PDF

38. Legends of supplementary figure 1 and 2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Conforti, Fabio, primary, Pala, Laura, primary, Pagan, Eleonora, primary, Bagnardi, Vincenzo, primary, De Pas, Tommaso, primary, Queirolo, Paola, primary, Pennacchioli, Elisabetta, primary, Catania, Chiara, primary, Cocorocchio, Emilia, primary, Ferrucci, Pier Francesco, primary, Saponara, Maristella, primary, Orsolini, Gianmarco, primary, Zagami, Paola, primary, Nicoló, Eleonora, primary, De Marinis, Filippo, primary, Tortora, Giampaolo, primary, Bria, Emilio, primary, Minucci, Saverio, primary, Joffe, Hadine, primary, Veronesi, Paolo, primary, Wargo, Jennifer, primary, Rosenthal, Rachel, primary, Swanton, Charles, primary, Mantovani, Alberto, primary, Gelber, Richard D., primary, Viale, Giuseppe, primary, Goldhirsch, Aron, primary, and Giaccone, Giuseppe, primary

Published
2023
Full Text
View/download PDF

40. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis

Author

Pala, Laura, primary, De Pas, Tommaso, additional, Pagan, Eleonora, additional, Minucci, Saverio, additional, Catania, Chiara, additional, Digiacomo, Nunzio, additional, Cocorocchio, Emilia, additional, Laszlo, Daniele, additional, Muzio, Antonio Di, additional, Barigazzi, Chiara, additional, Stucchi, Erika, additional, De Grandi, Laura, additional, Stucchi, Sara, additional, Viale, Giuseppe, additional, Gelber, Richard D., additional, Bagnardi, Vincenzo, additional, and Conforti, Fabio, additional

Published
2023
Full Text
View/download PDF

41. Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials

Author

Pala, Laura, De Pas, Tommaso, Pagan, Eleonora, Sala, Isabella, Catania, Chiara, Zattarin, Emma, Arnone, Paolo, Grassi, Massimo Maria, Colleoni, Marco Angelo, Wolff, Antonio C, Cortes, Javier, Piccart-Gebhart, Martine, Gelber, Richard, Viale, Giuseppe, Bagnardi, Vincenzo, Conforti, Fabio, Pala, Laura, De Pas, Tommaso, Pagan, Eleonora, Sala, Isabella, Catania, Chiara, Zattarin, Emma, Arnone, Paolo, Grassi, Massimo Maria, Colleoni, Marco Angelo, Wolff, Antonio C, Cortes, Javier, Piccart-Gebhart, Martine, Gelber, Richard, Viale, Giuseppe, Bagnardi, Vincenzo, and Conforti, Fabio

Abstract

Background: Controversy exists regarding the optimal duration of the extended adjuvant endocrine treatment (ET) in patients with early-stage breast-cancer (eBC). We performed a systematic review and trial-level meta-analysis of all randomized clinical trials (RCTs) comparing a “limited-extended” adjuvant ET (defined as more than 5 but less than 7.5 years of treatment overall) versus a “full-extended” adjuvant ET (defined as more than 7.5 years of treatment overall) in eBC. Methods: To be eligible, RCTs had to i) compare a “limited-extended” adjuvant ET versus a “full-extended” adjuvant ET in patients with eBC; and ii) report disease-free survival (DFS) hazard ratio (HR) according to the disease nodal-status [i.e. nodal-negative (N-ve) versus nodal-positive (N + ve)]. The primary endpoint was to assess the difference in efficacy of full-versus limited-extended ET, measured in terms of the difference in DFS log-HR, according to the disease nodal-status. Secondary endpoint was the difference in efficacy of full-versus limited-extended ET according to tumor size (i.e. pT1 vs pT2/3/4), histological grade (i.e. G1/G2 vs G3), patients’ age (i.e. ≤60 vs > 60 years) and previous type of ET (i.e. aromatase inhibitors vs tamoxifen vs switch strategy). Results: Three phase III RCTs fulfilled the inclusion criteria. A total of 6689 patients were included in the analysis, of which 3506 (53%) had N + ve disease. The full-extended ET provided no DFS-benefit as compared with the limited-extended ET in patients with N-ve disease (pooled DFS-HR = 1.04, 95%CI: 0.89 to 1.22; I2 = 18%). Conversely, in patients with N + ve disease the full-extended ET significantly improved DFS, with a pooled DFS-HR of 0.85 (95%CI: 0.74 to 0.97; I2 = 0%). There was a significant interaction between the disease nodal-status and the efficacy of the full-versus limited-extended ET (p-heterogeneity = 0.048). The full-extended ET provided no significant DFS-benefit as compared with the limited-extended ET in a, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

42. Genetic Alterations of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis

Author

Pala, Laura, primary, Bagnardi, Vincenzo, additional, Tettamanzi, Francesca, additional, Barberis, Massimo, additional, Mazzarol, Giovanni, additional, Casali, Cecilia, additional, De Pas, Tommaso, additional, Pennacchioli, Elisabetta, additional, Coppola, Sara, additional, Baldini, Federica, additional, Cocorocchio, Emilia, additional, Ferrucci, Pierfrancesco, additional, Patane’, Damiano, additional, Saponara, Maristella, additional, Queirolo, Paola, additional, and Conforti, Fabio, additional

Published
2022
Full Text
View/download PDF

44. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer

Author

Conforti, Fabio, primary, Pala, Laura, additional, Bagnardi, Vincenzo, additional, De Pas, Tommaso, additional, Colleoni, Marco, additional, Buyse, Marc, additional, Hortobagyi, Gabriel, additional, Gianni, Luca, additional, Winer, Eric, additional, Loibl, Sibylle, additional, Cortes, Javier, additional, Piccart, Martine, additional, Wolff, Antonio C., additional, Viale, Giuseppe, additional, and Gelber, Richard D., additional

Published
2022
Full Text
View/download PDF

46. Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy

Author

Corti, Chiara, primary, Conforti, Fabio, additional, Pala, Laura, additional, Catania, Chiara, additional, Cocorocchio, Emilia, additional, Ferrucci, Pier Francesco, additional, Curigliano, Giuseppe, additional, Queirolo, Paola, additional, and de Pas, Tommaso, additional

Published
2022
Full Text
View/download PDF

48. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials

Author

Pala, Laura, primary, Sala, Isabella, additional, Oriecuia, Chiara, additional, De Pas, Tommaso, additional, Queirolo, Paola, additional, Specchia, Claudia, additional, Cocorocchio, Emilia, additional, Ferrucci, Pierfrancesco, additional, Patanè, Damiano, additional, Saponara, Maristella, additional, Pennacchioli, Elisabetta, additional, Coppola, Sara, additional, Viale, Giuseppe, additional, Giaccone, Giuseppe, additional, Gelber, Richard D., additional, Bagnardi, Vincenzo, additional, and Conforti, Fabio, additional

Published
2022
Full Text
View/download PDF

49. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study

Author

Conforti, Fabio, primary, Gronchi, Alessandro, additional, Penel, Nicholas, additional, Jones, Robin L., additional, Broto, Javier M., additional, Sala, Isabella, additional, Bagnardi, Vincenzo, additional, Napolitano, Andrea, additional, Pala, Laura, additional, Pennacchioli, Elisabetta, additional, Catania, Chiara, additional, Queirolo, Paola, additional, Grigani, Giovanni, additional, Merlini, Alessandra, additional, Stacchiotti, Silvia, additional, Comandone, Alessandro, additional, Vincenzi, Bruno, additional, Quagliuolo, Vittorio, additional, Bertuzzi, Alexia, additional, Boglione, Antonella, additional, Palassini, Elena, additional, Baldi, Giacomo G., additional, Blay, Jean-Yves, additional, Ryckewaert, Thomas, additional, Toulmonde, Maud, additional, Italiano, Antoine, additional, Le Cesne, Axel, additional, Ray-Coquard, Isabelle, additional, Cruz, Josefina, additional, Hernández-León, Carmen N., additional, Trufero, Javier M., additional, da Silva Moura, David, additional, Muñiz, Nadia H., additional, and De Pas, Tommaso, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results